Healthcare Resource Utilization Pre- and Post-Initiation of Eslicarbazepine Acetate Among Pediatric Patients with Focal Seizure: Evidence from Routine Clinical Practice

References

• Zack MM, Kobau R. National and state estimates of the numbers of adults and children with active epilepsy—United States, 2015. MMWR Morb Mortal Wkly Rep. 2017;66(31):821–825. doi:10.15585/mmwr.mm6631a1
   PubMed Web of Science ®Google Scholar
• Sillanpää M, Jalava M, Shinnar S. Epilepsy syndromes in patients with childhood-onset seizures in Finland. Pediatr Neurol. 1999;21(2):533–537. doi:10.1016/s0887-8994(99)00031-4
   Web of Science ®Google Scholar
• Lekoubou A, Bishu KG, Ovbiagele B. The direct cost of epilepsy in children: evidence from the medical expenditure panel survey, 2003–2014. Epilepsy Behav. 2018;83:103–107. doi:10.1016/j.yebeh.2018.03.020
   Web of Science ®Google Scholar
• Cramer JA, Wang ZJ, Chang E, et al. Healthcare utilization and costs in children with stable and uncontrolled epilepsy. Epilepsy Behav. 2014;32:135–141. doi:10.1016/j.yebeh.2014.01.016
   PubMed Web of Science ®Google Scholar
• Wei SH, Lee WT. Comorbidity of childhood epilepsy. J Formos Med Assoc. 2015;114(11):1031–1038. doi:10.1016/j.jfma.2015.07.015
   Web of Science ®Google Scholar
• Baca CB, Vickrey BG, Caplan R, Vassar SD, Berg AT. Psychiatric and medical comorbidity and quality of life outcomes in childhood-onset epilepsy. Pediatrics. 2011;128(6):e1532–e1543. doi:10.1542/peds.2011-0245
   PubMed Web of Science ®Google Scholar
• Oh A, Thurman DJ, Kim H. Comorbidities and risk factors associated with newly diagnosed epilepsy in the U.S. pediatric population. Epilepsy Behav. 2017;75:230–236. doi:10.1016/j.yebeh.2017.07.040
   Web of Science ®Google Scholar
• Russ SA, Larson K, Halfon N. A national profile of childhood epilepsy and seizure disorder. Pediatrics. 2012;129(2):256–264. doi:10.1542/peds.2010-1371
   PubMed Web of Science ®Google Scholar
• Mula M. Treatment-emergent psychiatric adverse events of antiepileptic drugs in epilepsy: how can we avoid them? Neuropsychiatry. 2011;1(4):371–376. doi:10.2217/npy.11.29
   Google Scholar
• Mula M, Sander JW. Negative effects of antiepileptic drugs on mood in patients with epilepsy. Drug Saf. 2007;30(7):555–567. doi:10.2165/00002018-200730070-00001
   PubMed Web of Science ®Google Scholar
• Chen B, Detyniecki K, Choi H, et al. Psychiatric and behavioral side effects of anti-epileptic drugs in adolescents and children with epilepsy. Eur J Paediatr Neurol. 2017a;21(3):441–449. doi:10.1016/j.ejpn.2017.02.003
   Web of Science ®Google Scholar
• Chen B, Choi H, Hirsch LJ, et al. Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy. Epilepsy Behav. 2017b;76:24–31. doi:10.1016/j.yebeh.2017.08.039
   PubMed Web of Science ®Google Scholar
• Weintraub D, Buchsbaum R, Resor SR, Hirsch LJ. Psychiatric and behavioral side effects of the newer antiepileptic drugs in adults with epilepsy. Epilepsy Behav. 2007;10(1):105–110. doi:10.1016/j.yebeh.2006.08.008
   PubMed Web of Science ®Google Scholar
• Glauser T, Ben-Menachem E, Bourgeois B, et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2006;47(7):1094–1120. doi:10.1111/j.1528-1167.2006.00585.x
   PubMed Web of Science ®Google Scholar
• Snead OC, Donner EJ. A new generation of anticonvulsants for the treatment of epilepsy in children. Paediatr Child Health. 2007;12(9):741–744. doi:10.1093/pch/12.9.741
   Web of Science ®Google Scholar
• Moavero R, Santarone ME, Galasso C, Curatolo P. Cognitive and behavioral effects of new antiepileptic drugs in pediatric epilepsy. Brain Dev. 2017;39(6):464–469. doi:10.1016/j.braindev.2017.01.006
   PubMed Web of Science ®Google Scholar
• APTIOM® Prescribing Information. Retrieved January 18, 2020. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022416s000lbl.pdf. Accessed July 10, 2020.
   Google Scholar
• US Department of Health & Human Services. Federal policy for the protection of human subjects (‘common rule’). Available from: https://www.hhs.gov/ohrp/regulations-and-policy/regulations/common-rule/index.html. Accessed April 20, 2020..
   Google Scholar
• Aaberg KM, Bakken IJ, Lossius MI, et al. Comorbidity and childhood epilepsy: a nationwide registry study. Pediatrics. 2016;138(3):e20160921–e20160921. doi:10.1542/peds.2016-0921
   Web of Science ®Google Scholar
• Mehta D, Lee A, Simeone J, Nordstrom B Characteristics of adult patients with focal seizure receiving eslicarbazepine acetate therapy in routine clinical practice: evidence from a large US commercial claims database [abstract]. American Epilepsy Society Annual Meeting 2018. 2018. Available from: https://www.aesnet.org/meetings_events/annual_meeting_abstracts/view/500810. Accessed July 10, 2020.
   Google Scholar
• Faught E, Li X, Choi J, Malhotra M, Knoth R. Inpatient hospitalization risk in patients with epilepsy before and after perampanel treatment [abstract]. Neurology. 2019;92(15Supplement):P3.5–022.
   Google Scholar
• Chatterjee D, Li X, Malhotra M, Choi J Inpatient hospitalization risk in medicaid patients with epilepsy before and after perampanel treatment [abstract]. American Academy of Neurology Annual Meeting 2019. 2019. Available from: http://indexsmart.mirasmart.com/AAN2019/PDFfiles/AAN2019-001535.pdf. Accessed July 10, 2020.
   Google Scholar
• Doherty CP, Rheims S, Assenza G, et al. Eslicarbazepine acetate in epilepsy patients with psychiatric comorbidities and intellectual disability: clinical practice findings from the Euro-Esli study. J Neurol Sci. 2019;402:88–99. doi:10.1016/j.jns.2019.04.040
   Web of Science ®Google Scholar
• Shankar R, Henley W, Allard J, et al. Comparing response of eslicarbazepine acetate between people with intellectual disability (ID) and general population – results from the Ep-ID UK register [abstract]. American Epilepsy Society Meeting 2019. 2019. Available from: https://www.aesnet.org/meetings_events/annual_meeting_abstracts/view/2422217. Accessed July 10, 2020.
   Google Scholar
• Jóźwiak S, Veggiotti P, Moreira J, Gama H, Rocha F, Soares-da-Silva P. Effects of adjunctive eslicarbazepine acetate on neurocognitive functioning in children with refractory focal-onset seizures. Epilepsy Behav. 2018;81:1–11. doi:10.1016/j.yebeh.2018.01.029
   PubMed Web of Science ®Google Scholar
• Kirkham F, Auvin S, Moreira J, et al. Efficacy and safety of eslicarbazepine acetate as adjunctive therapy for refractory focal-onset seizures in children: a double-blind, randomized, placebo-controlled, parallel-group, multicenter, phase-III clinical trial. Epilepsy Behav. 2020;105:106962. doi:10.1016/j.yebeh.2020.106962
   Web of Science ®Google Scholar
• Mintz M, Pina-Garza JE, Wolf SM, et al. Safety and tolerability of adjunctive eslicarbazepine acetate in pediatric patients (aged 4–17 years) with focal seizures. J Child Neurol. 2020;35(4):265–273. doi:10.1177/0883073819890997
   Web of Science ®Google Scholar
• Tanritanir A, Wang X, Loddenkemper T. Experience with eslicarbazepine acetate treatment at a pediatric epilepsy center [abstract]. Neurology. 2019;92(15Supplement):P5.5–013.
   Google Scholar
• Lekoubou A, Bishu KG, Ovbiagele B. Nationwide healthcare utilization among children with epilepsy in the United States: 2003–2014. Epilepsy Res. 2018b;141:90–94. doi:10.1016/j.eplepsyres.2018.02.012
   Web of Science ®Google Scholar
• Puka K, Smith ML, Moineddin R, Snead OC, Widjaja E. Health resource utilization varies by comorbidities in children with epilepsy. Epilepsy Behav. 2016;57(Pt A):151–154. doi:10.1016/j.yebeh.2016.02.011
   Web of Science ®Google Scholar
• Jalihal V, Shankar R, Henley W, et al. Eslicarbazepine acetate as a replacement for levetiracetam in people with epilepsy developing behavioral adverse events. Epilepsy Behav. 2018;80:365–369. doi:10.1016/j.yebeh.2018.01.020
   PubMed Web of Science ®Google Scholar